Finance

Beta
Lists
ATNM:NYSEAMERICAN
Actinium Pharmaceuticals Inc
$1.10
-0.90%
(-0.0100) 1D
Jun 5, 2:55:14 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ATNM...
Open
$1.11
High
$1.14
Low
$1.10
Mkt. cap
33.88M
Avg. vol.
124.08K
Volume
124.19K
52-wk high
$1.95
52-wk low
$0.95
EPS
-$0.75
Beta
-0.06
Shares outstanding
31.38M
No. of employees
25
Open
$1.11
High
$1.14
Low
$1.10
Mkt. cap
33.88M
Avg. vol.
124.08K
Volume
124.19K
52-wk high
$1.95
52-wk low
$0.95
EPS
-$0.75
Beta
-0.06
Shares outstanding
31.38M
No. of employees
25
Analyst outlook
Analyst Ratings
Based on 3 analysts giving stock ratings to ATNM in the past 3 months
Strong Buy
Buy
3
Hold
0
Sell
0
12 month forecast
Based on 3 Wall Street analysts offering 12 month price targets for ATNM in the last 3 months.
Highest
Current $1.10
$9.00 (+718.18%)
Average
$6.00 (+445.45%)
Lowest
$4.00 (+263.64%)
News stories
From sources across the web
About Actinium Pharmaceuticals Inc
CEOSandesh Seth
Employees25
Founded2000
Headquarters-
SectorBiotechnology
Websiteactiniumpharma.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
90.00K
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
4.88M
4.25M
4.30M
4.20M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2.62M
1.53M
2.12M
1.70M
Operating expense
7.50M
5.78M
6.41M
5.90M
Total operating expenses
7.50M
5.78M
6.41M
5.90M
Operating income
-7.50M
-5.69M
-6.41M
-5.90M
Other non operating income
-
-
-
-
EBT including unusual items
-6.88M
-5.13M
-5.94M
-5.52M
EBT excluding unusual items
-6.88M
-5.13M
-5.94M
-5.52M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-6.88M
-5.13M
-5.94M
-5.52M
Net profit margin
-
-5,701.11%
-
-
Earnings per share
-0.22
-0.16
-0.19
-0.18
Interest and investment income
625.00K
561.00K
474.00K
381.00K
Interest expense
-
-
-
-
Net interest expenses
625.00K
561.00K
474.00K
381.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-7.30M
-5.49M
-6.37M
-5.87M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer